|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Collaboration revenue | ||
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income (expense), net: | ||
| Interest expense | ||
| Interest and other income (expense), net | ||
| Gain (loss) from changes in fair value of warrants | ||
| Loss on extinguishment of debt | ||
| Total other income (expense), net | ||
| Net loss | ||
| Unrealized holding gains on available-for-sale investments | ||
| Foreign currency translation adjustment | ||
| Total other comprehensive income | ||
| Total comprehensive loss | ||
| Net loss per share attributable to common stockholders, Basic | ||
| Net loss per share attributable to common stockholders, Diluted | ||
| Weighted-average common shares outstanding, basic | ||
| Weighted-average common shares outstanding, dilutive |
Loading...
